How to optimize outpatient delivery of bispecific antibody therapy for MM
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
How to optimize outpatient delivery of bispecific antibody therapy for MM
-
ナレーター：
-
著者：
The Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked how to optimize outpatient delivery of bispecific antibody therapy for multiple myeloma (MM).
In this interview, Popat discusses practical strategies to support the outpatient delivery of bispecific antibody therapy, including patient selection, caregiver support, and access to timely medical care if needed. Popat also outlines approaches that could facilitate step-up dosing in the outpatient setting, such as strategies to reduce the risk of cytokine release syndrome (CRS) and the potential use of wearable technology and remote monitoring.
Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.